DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT - Get Free Report) in a research report issued on Monday. The brokerage set a "hold" rating on the stock.

DBVT has been the subject of a number of other research reports. JMP Securities reiterated a "market outperform" rating and set a $10.00 price target on shares of DBV Technologies in a report on Friday, January 10th. HC Wainwright boosted their price objective on DBV Technologies from $25.00 to $35.00 and gave the stock a "buy" rating in a report on Thursday, October 24th.

DBV Technologies Price Performance

Shares of DBVT traded up $0.23 during midday trading on Monday, hitting $4.35. The stock had a trading volume of 10,814 shares, compared to its average volume of 108,559. The company has a 50 day simple moving average of $3.89 and a two-hundred day simple moving average of $3.86. DBV Technologies has a twelve month low of $2.20 and a twelve month high of $9.40. The firm has a market cap of $89.48 million, a price-to-earnings ratio of -0.97 and a beta of 0.67.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.